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S34 Am J PBackground: The International Agency for Research on Cancer determination that shift work is a
“probable” human carcinogen was based primarily on studies of breast cancer but it was also noted
that additional aspects of circadian disruption and other cancer sites deserved further research.
Purpose: To examine possible associations of three measures of circadian disruption: nontypical
work schedules, nightly sleep duration, and monthly frequency of insomnia with risk of fatal ovarian
cancer in a sample of American women.
Methods: Several measures of circadian disruption and other information were assessed in 1982
from 161,004 employed women in the American Cancer Society’s Cancer Prevention Study–II, a
cohort that has been followed for mortality through 2010. In 2013, Cox proportional hazards
regression was used to model the relative risks (RRs) and 95% CIs of death from ovarian cancer for
categories of each indicator of circadian disruption.
Results: Over 28 years of follow-up, 1289 deaths from ovarian cancer occurred in the at-risk
cohort. Compared to ﬁxed daytime work, a rotating schedule was associated with an elevated risk of
fatal ovarian cancer (RR¼1.27, 95% CI¼1.03, 1.56). No signiﬁcant associations were observed for
sleep duration (p trend¼0.24) or insomnia (p trend¼0.44).
Conclusions: In this large prospective study, there was a higher risk of fatal ovarian cancer in
women who reported a rotating work schedule. These ﬁndings and the high prevalence of rotating
shift schedules underscore the need for further research examining the role of work schedule and
risk of ovarian cancer.
(Am J Prev Med 2014;46(3S1):S34–S41) & 2014 American Journal of Preventive Medicine
Open access under CC BY-NC-ND license.IntroductionIn 2004, the Bureau of Labor Statistics (BLS) reportedthat 83.9% of employed women worked typical day-time schedules, deﬁned by the BLS as between the
hours of 6:00AM and 6:00PM. Fewer women, 11.5%, worked
schedules that took them into the evening (between 2:00PM
and 12MN); night (between 9:00PM and 8:00AM); or that
rotated periodically.1 Accumulated evidence suggests that
working during the night has important physiological
consequences and in 2007 the International Agency for
Research on Cancer (IARC) concluded that shift work
involving circadian disruption was “probably carcino-
genic.”2 IARC based this report on animal studies and
limited evidence from occupational cohorts. The associa-
tion is most convincing for breast cancer3–8 but also wasdemiology Research Program, American Cancer Society,
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Open access uobserved for prostate,9 colorectal,10 and endometrial11
cancers. The working group discussed the need to explore
these associations with additional cancer sites as well as
other aspects of circadian disruption such as other non-
traditional work schedules or sleep duration and quality.12
Retinal exposure to light stimulates the pineal gland to
modulate levels of melatonin,13 and the response to the
24-hour day–night cycle is a powerful physiological
synchronizer.14,15 In the late 1970s, Cohen et al.16
hypothesized that pineal gland dysfunction was linked
to breast cancer after they observed that melatonin
inhibits pituitary gonadotropins. Later studies found
that women working night shifts were more likely to
report irregular menstrual cycles, fertility problems, and
negative birth outcomes due to disrupted sex hormone
levels17,18; these hormones are important in the etiology
of reproductive cancers.19 Moreover, animal experi-
ments have shown that nocturnal physiological levels
of melatonin have direct anti-proliferative and anti-
metastatic effects on cancer cells.20,21
There is limited evidence demonstrating an association
between circadian rhythm disruption and risk of ovarianrican Journal of Preventive Medicine  Published by Elsevier Inc.
nder CC BY-NC-ND license.
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invasive ovarian cancer cases found signiﬁcantly increased
odds of ever working night shifts in women with cancer
compared to the controls22; however, there was no dose–
response with longer duration. In contrast, an earlier
analysis of Nurses’ Health Studies (NHS)–I and –II found
no association between duration of rotating shift schedules
and incident ovarian cancer.23 Only one study has exam-
ined sleep duration as a measure of circadian disruption. A
small Japanese cohort reported an inverse association
between sleep duration and incident ovarian cancer24;
however, that analysis included only 86 total cases and
did not examine work schedule. None of the studies of
circadian disruption–related factors and ovarian cancer
have investigated sleep and work schedule concurrently.
The Cancer Prevention Study–II (CPS–II) is a large
nationwide prospective mortality cohort of men and
women followed for 28 years. The primary aims of this
analysis were to examine whether three indicators of
circadian disruption (i.e., work schedule, average sleep
duration, and frequency of insomnia) were associated
with risk of dying from ovarian cancer in this cohort.
Secondary aims were to evaluate whether the association
between sleep duration and ovarian cancer mortality are
modiﬁed by BMI or work schedule, and whether results
differed by follow-up period.
Methods
The Cancer Prevention Study–II Cohort
In 1982, the American Cancer Society initiated the CPS–II
mortality cohort to identify risk factors for and opportunities to
prevent cancer. Volunteers enrolled 1.2 million men and women in
all 50 states, the District of Columbia, and Puerto Rico. Each
returned a mailed four-page questionnaire that provided informa-
tion on demographic factors, reproductive health, diet and
nutrition, height and weight, current and past use of tobacco
products, as well as personal and family medical histories. More
detailed discussions of the Cancer Prevention Studies are available
elsewhere.25,26 Every aspect of CPS–II is approved and monitored
by the Emory University School of Medicine IRB.
Women were excluded from this analysis if they reported any of
the following at baseline: prevalent cancer other than nonmela-
noma skin cancer (n=57,094); history of ovarian surgeries or
hysterectomies (n=172,892); women who did not indicate their
menopausal status or reported it as “artiﬁcially” induced
(n=45,541); did not respond to questions of current rotating work
schedule (n=171,366); ﬁxed-schedule workers who did not dis-
close the time of day they began working (n=22,508); or who were
not currently employed (n=45,755). The ﬁnal analytic cohort
included 161,004 employed women with a mean age of 50.3 years.
Assessment of Circadian Disruption
Three indicators of circadian disruption were considered in this
analysis: work schedule, average sleep duration, and frequency ofMarch 2014insomnia. The CPS–II questionnaire asked participants to answer
Do you work rotating shifts? and What time of day do you start
working? Their responses were combined to create a single variable
for work schedule based on BLS deﬁnitions1 and assuming an
8-hour workday. Rotating schedule workers were those who self-
identiﬁed as so; all others were considered to work ﬁxed schedules.
Fixed daytime workers started work between 6:00AM and 10:00AM;
ﬁxed afternoon/evening workers began 2:00PM to 4:00PM; ﬁxed
night workers began 9:00PM to 12MN. Very few women began their
workday outside of these hours and were not well deﬁned within
BLS descriptions; they were classiﬁed as “other.”
To evaluate sleep quality and duration, participants were asked:
On the average, how many hours do you sleep each night? and
responses were categorized as 3–5, 6, 7, 8, and 9–12 hours; outliers
or missing responses were combined as a separate category.
Statistical models compared each group to participants who sleep
7 hours, similar to previous studies of sleep in this cohort.27,28
Insomnia was assessed by asking: On the average, how many times
per month do you have insomnia? and categorized as r1, 2, 3–9,
and Z10 nights per month; each was compared to participants
reporting no insomnia.Mortality Follow-Up
Prior to 1988, American Cancer Society volunteers made personal
inquiries to determine the vital status of each CPS–II participant.
Death certiﬁcates were obtained and the underlying cause of death
was recorded. Subsequently, automatic linkages with the National
Death Index have been completed biennially and mortality follow-
up is current through December 31, 2010. Underlying cause of
death is established for 99.4% of all known deaths. Ovarian cancer
was coded according to ICD-929 codes 183.0–183.9, and ICD-1030
codes C56, and C57.0–C57.4. There were a total of 1289 ovarian
cancer deaths identiﬁed in the at-risk cohort.Statistical Analysis
All statistical analyses were conducted in SAS v9.3. Follow-up time
in years was computed for each individual as the time since
enrollment in 1982 until the date of death or December 31, 2010,
whichever was earliest. Age- and multivariable-adjusted Cox
proportional hazards regression modeling was used to evaluate
possible associations between each of the indicators of circadian
disruption (i.e., work schedule, duration of sleep, and frequency of
insomnia) and death from ovarian cancer. Trend variables for
sleep duration and frequency of insomnia were derived by using
the median value from each category and then modeling this as a
continuous variable. All models stratiﬁed on single year of age at
enrollment. Multivariable models adjusted for covariates found to
be signiﬁcant risk factors for ovarian cancer in this cohort31; these
included categorical variables for race, family history of breast or
ovarian cancer, age at menarche, menopausal status, age at
menopause, age at ﬁrst birth, parity, duration of oral contraceptive
use, postmenopausal estrogen use, and previous tubal ligation.
Continuous measures were used for BMI and height. Education,
alcohol use, smoking status, and use of sleeping pills were not
signiﬁcantly associated with the primary exposure variables or fatal
ovarian cancer; consequently, they were not included in the
ﬁnal model.
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the association between sleep and fatal ovarian cancer by BMI or
work schedule was assessed by creating cross-product interaction
terms for categories of sleep and WHO BMI categories32 and sleep
and work schedule; the results were compared to the base model
using likelihood ratio tests. To evaluate the degree to which
misclassiﬁcation would bias the results as the cohort aged and left
the workforce, follow-up time was divided in half, from 1982 to
1995 and 1996 to 2010.
Results
The distribution of baseline characteristics according to
work schedule for the analytic cohort is shown in Table 1.
The mean age in 1982 was 50.3 years. The majority of the
women were white (92%); educated beyond high school
(64.4%); not menopausal at baseline (53.4%); reported
never taking oral contraceptives (57.6%); got moderate
exercise (61.7%); and had a BMI o25.0 (65.2%). Only
6.6% of the cohort reported working a rotating schedule
in 1982 and much smaller proportions worked ﬁxed
afternoon/evening or night shifts. Nearly all (90.9%)
women reported that they slept between 6 and 8 hours
a night and more than half (56.1%) did not report
insomnia. Between 1982 and 2010, there were 1289
deaths from ovarian cancer over 4,146,706 person-years
of follow-up.
Women working each schedule did not differ remark-
ably in age, BMI, height, or frequency of insomnia. A
greater proportion of black women, those who did not
complete high school, and heavy exercisers reported
rotating schedules than did other women. The same
groups were more likely to indicate either extreme of
sleep duration (Appendix A, available online at www.
ajpmonline.org). White women and ever postmeno-
pausal estrogen users reported more frequent insomnia;
otherwise, there were no differences (Appendix B,
available online at www.ajpmonline.org).
A signiﬁcant elevated risk of fatal ovarian cancer was
observed with women reporting rotating work schedules
in 1982 compared to ﬁxed day workers after adjusting for
reproductive, anthropometric, and other risk factors
(RR¼1.27, 95% CI¼1.03, 1.56; Table 2), an association
that was robust throughout the entire follow-up
(Figure 1). Fixed afternoon/evening or night shifts were
not associated with fatal ovarian cancer. There were no
associations observed with sleep duration (p trend¼
0.2416) or insomnia (p trend¼0.4438).
In sensitivity analyses, the association between sleep
duration and ovarian cancer was not modiﬁed by BMI
categories (p interaction¼0.513), or by rotating work
schedule (p interaction¼0.483). When the analyses were
stratiﬁed by follow-up time, results of sleep duration and
insomnia remained unremarkable. The general patternobserved with rotating shift schedules persisted in both
time periods: it did not reach signiﬁcance in the ﬁrst half,
although it did in the second: RR¼1.14 (95% CI¼0.79,
1.63) and RR¼1.34 (95% CI¼1.05, 1.72).
Discussion
In this large prospective study of employed women,
working rotating shifts was signiﬁcantly associated with a
moderately elevated risk of fatal ovarian cancer com-
pared to a ﬁxed day schedule beginning between 6:00AM
and 10:00AM. No associations were observed for sleep
duration or insomnia. Although the RR associated with
working a rotating schedule is modest (1.27), it is of
similar magnitude to other ovarian cancer risk factors
observed in this cohort.31,33–38
These ﬁndings and those from other studies do not
provide clear evidence of the relationship between
circadian disruption and ovarian cancer. Differences in
study design, exposure deﬁnitions, and outcomes might
explain, in part, inconsistencies across studies. In this
analysis of CPS–II, there was no association of current
night shift work with fatal ovarian cancer and a positive
association of rotating shifts with fatal ovarian cancer.
However, a large case–control study found a signiﬁcant
positive association for night work but did not speciﬁ-
cally collect information on rotating schedules.22 Impor-
tantly, very few women in CPS–II reported ﬁxed night
work and therefore power was limited for the exposure.
In CPS–II and in the NHS,23 self-reported work schedule
information was collected prospectively; however, in the
NHS, detailed information on work schedule was col-
lected in repeated follow-ups whereas in CPS–II, infor-
mation was collected only at baseline. Therefore, the
deﬁnitions of rotating shift work differed between the
two studies. More speciﬁcally, in the NHS, rotating shift
was deﬁned as at least 3 nights per month working at
night in addition to day or evening shifts; in contrast,
CPS–II participants were asked to simply report if they
were currently working rotating shift schedules.
Given the repeated measures over time in the NHS,
there is likely to be less misclassiﬁcation over time,
whereas in CPS–II this misclassiﬁcation is likely to
attenuate any associations. This nondifferential misclas-
siﬁcation in CPS–II over time does not explain the
observed association between rotating shift work and
risk of ovarian cancer. Further, the case–control and
NHS studies evaluated association between shift work
and ovarian cancer incidence, whereas the outcome for
the CPS–II was mortality. Although most risk factors are
observed consistently across most subtypes of ovarian
cancer,39 it is possible that rotating shift work might be
differentially associated with highly fatal diseasewww.ajpmonline.org















Age (M [SD]) 161,004 50.3 (8.6) 49.7 (9.4) 50.6 (6.5) 49.9 (9.1) 51.1 (9.5)
BMI (M [SD]) 24.4 (4.5) 24.8 (4.7) 25.2 (5.0) 26.3 (5.7) 25.0 (4.9)
Height (cm; M [SD]) 163.9 (6.6) 163.7 (6.7) 163.8 (6.9) 163.8 (6.9) 163.5 (6.6)
Hours of sleep (M [SD]) 7.2 (0.9) 7.2 (1) 7.2 (1) 6.8 (1.2) 7.2 (1.1)
Monthly frequency of
insomnia (M [SD])
1.5 (3.1) 1.7 (3.5) 1.6 (3.3) 1.4 (3.0) 1.6 (3.3)
Race
White 148,436 (92.2) 88.2 6.4 1.4 1.1 2.9
Black 8,085 (5.0) 84.5 8.6 1.7 1.7 3.6
Other 4,483 (2.8) 86.1 8.1 1.5 0.9 3.4
Family history of breast/ovarian cancers
No 149,274 (92.7) 87.9 6.6 1.4 1.1 2.9
Yes 11,730 (7.3) 88.4 6.3 1.5 1.0 2.9
Age at menarche
r12 71,990 (44.7) 88.3 6.3 1.4 1.2 2.9
13 46,113 (28.6) 88.2 6.4 1.4 1.0 2.9
Z13 40,017 (24.9) 87.2 7.2 1.4 1.0 3.1
Age at menopause
Pre-/peri-menopausal 85,903 (53.4) 88.0 6.8 1.3 1.1 2.8
o50 years 30,471 (18.9) 87.9 6.3 1.5 1.1 3.1
Z50 years 39,232 (24.4) 88.2 5.9 1.6 1.1 3.2
Parity/age of ﬁrst birth
Nulliparous 21,937 (13.6) 90.4 5.7 1.2 0.8 2.0
1–2 births, o25 years
old
30,011 (18.6) 89.1 5.9 1.3 0.9 2.8
1–2 births, Z25 years
old
29,465 (18.3) 90.1 5.3 1.1 0.9 2.6
Z3 births, o25 years
old
52,710 (32.7) 85.8 7.6 1.8 1.3 3.5
Z3 births, Z25 years
old
20,683 (12.8) 87.2 6.5 1.6 1.5 3.2
Duration of oral contraceptive use
Never 92,771 (57.6) 87.9 6.3 1.5 1.2 3.1
o5 years 32,763 (20.3) 87.8 7.0 1.4 1.1 2.8
Z5 years 29,926 (18.6) 89.1 6.4 1.2 0.9 2.5
(continued on next page)
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Pre-/peri-menopausal 85,903 (53.4) 88.0 6.8 1.3 1.1 2.8
Never 47,294 (29.4) 88.4 5.9 1.5 1.1 3.1
Ever 21,183 (13.2) 88.2 6.2 1.5 1.0 3.0
Tubal ligation
No 143,937 (89.4) 88.1 6.5 1.4 1.1 3.0
Yes 17,067 (10.6) 87.1 7.0 1.6 1.4 2.9
Education
oHigh school degree 9,691 (6.0) 79.1 10.6 2.1 1.5 6.6
High school graduate 46,423 (28.8) 87.7 6.5 1.3 0.8 3.8
Vocational/some
college
51,224 (31.8) 87.3 7.0 1.7 1.4 2.7
College graduate 52,418 (32.6) 90.8 5.3 1.2 0.9 1.8
Exercise
None/slight 50,285 (31.2) 91.8 4.6 0.8 0.7 2.1
Moderate 99,288 (61.7) 86.9 7.1 1.6 1.2 3.2
Heavy 9,383 (5.8) 79.7 11.2 2.6 1.4 5.2
ERT, estrogen replacement therapy
Carter et al / Am J Prev Med 2014;46(3S1):S34–S41S38compared to less fatal ovarian cancer. Importantly,
despite the differences in design among studies, the null
results from NHS are compelling, because in that cohort,
signiﬁcant positive associations were reported of shift
work with risk of other cancers including breast,7,8
colorectal,10 and endometrial11 cancers. Regardless,
taken together, ﬁndings from these three studies cannot
rule out a possible association between work schedule
and risk of ovarian cancer, and further research inves-
tigating a comprehensive history of lifetime work is
warranted.
For sleep duration, the inverse association with inci-
dent ovarian cancer reported in a cohort of Japanese
women,24 was not observed in CPS–II. These two studies
differed most notably in the total number of cases
available for analysis. In CPS–II, there were 1289 ovarian
cancer deaths over 28 years of follow-up, whereas in the
Japanese study there were only 86 cases over 16 years.
Therefore it is unclear whether their ﬁndings are due to
chance, or due to underlying cultural and genetic differ-
ences between these populations.40 Unfortunately, CPS–II does not have sufﬁcient numbers of Asian Americans
to explore possible racial differences. However, this issue
deserves further research in other cohorts.
The biologic mechanisms underlying these associa-
tions are likely complex. There is considerable evidence
that circadian disruption, through exposure to light at
night, has profound effects on human health and risk of
cancer. Even small periods of nighttime light exposure
can signiﬁcantly affect plasma melatonin levels15 and
disrupt the body’s natural pacemaker.14 Human studies
show that hormone surges follow predictable circadian
patterns, and that disruptions in these rhythms are
strongly associated with reproductive dysfunction in
women41; these hormones are particularly important in
the development of reproductive cancers.42 More
directly, exposure to light at night can have nonhormo-
nal effects on cancer risk. Blask et al.20 exposed human
breast cancer xenografts in nude rats to melatonin
enriched or deﬁcient blood and found that melatonin
directly suppressed proliferative activity but that even
short-term light exposure would eliminate this beneﬁt.www.ajpmonline.org
Table 2. Results of Cox proportional hazards analyses for indicators of circadian disruption and fatal ovarian cancer
Deathsa Person-years RRb 95% CI RRc 95% CI
Work schedule
Fixed day 1,126 3,655,986 1.00 — 1.00 —
Rotating shifts 101 269,742 1.27 (1.04, 1.56) 1.27 (1.03, 1.56)
Fixed afternoon/evening 11 57,506 0.62 (0.34, 1.11) 0.62 (0.34, 1.12)
Fixed night 15 44,394 1.14 (0.68, 1.89) 1.12 (0.67, 1.87)
Sleep duration (hours)
3–5 41 135,499 0.99 (0.72, 1.37) 1.01 (0.73, 1.40)
6 230 681,793 1.13 (0.96, 1.32) 1.13 (0.97, 1.33)
7 453 1,566,880 1.00 — 1.00 —
8 493 1,526,660 1.16 (1.02, 1.31) 1.16 (1.02, 1.31)
9–12 58 203,872 1.08 (0.82, 1.42) 1.08 (0.82, 1.42)
p trend¼0.2689 p trend¼0.2416
Insomnia (nights/month)
Never 700 2,329,285 1.00 — 1.00 —
r1 115 378,778 0.98 (0.81, 1.20) 0.98 (0.8, 1.20)
2 138 432,378 0.99 (0.83, 1.19) 1.01 (0.84, 1.21)
3–9 228 662,491 1.02 (0.88, 1.19) 1.04 (0.89, 1.21)
Z10 30 129,390 0.69 (0.48, 0.99) 0.71 (0.49, 1.03)
p trend¼0.3213 p trend¼0.4438
aNumber of deaths do not equal total because “missing” categories are excluded.
bAge-adjusted
cMultivariable results are adjusted for oral contraceptive use, age at menarche and menopause, tubal ligation, parity, postmenopausal estrogen use,
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Figure 1. Cumulative hazards of fatal ovarian cancer asso-
ciated with rotating shift schedules and ﬁxed day schedules
Carter et al / Am J Prev Med 2014;46(3S1):S34–S41 S39The circadian system is modulated through at least nine
“clock” genes,43 many of which are important in cell
cycle regulation. There is active research linking dys-
function in these genes to cancer risk, and polymor-
phisms in the CLOCK, PER, and CRY genes are
important in the development of some breast44 and
ovarian45 tumors.
The strengths of this study are its prospective design
and long-term follow-up; it is remarkable for its large size
and inclusion of multiple measures of circadian disrup-
tion examined in relation to fatal ovarian cancer. One
limitation is that all of these exposures were self-reported
and assessed only at baseline. As people age, sleeping
patterns change and CPS–II participants would be
expected to have long sleep latency and shorter duration
over follow-up.46 Additionally, as women left the work-
force, rotating shift work would become increasingly
misclassiﬁed. Despite this, analyses stratiﬁed by follow-
up period did not suggest that misclassiﬁcation was a
major problem in this study. A second limitation was thatMarch 2014follow-up included only fatal ovarian cancers. Data
suggest that ovarian cancer is an aggregate of several
distinct diseases46,47; analyses by subtype are advised
where possible.
Carter et al / Am J Prev Med 2014;46(3S1):S34–S41S40In this study, there was a 27% higher risk of fatal
ovarian cancer in women working rotating shifts com-
pared to ﬁxed daytime schedules, whereas sleep duration
and frequency of insomnia were not associated. Further
research is needed to identify subgroups of women in
which circadian disruption may be more clinically mean-
ingful, for instance, women with a family history of
cancer or women who might not physiologically adapt
well to frequent rotating work shifts.Publication of this article was supported by the American
Cancer Society.
The publication of this supplement was made possible through
the CDC and the Association for Prevention Teaching and
Research (APTR) Cooperative Agreement No. 1 U360E000005-
01. The ﬁndings and conclusions in this report are those of the
authors and do not necessarily represent the ofﬁcial position of
the CDC or the APTR.
The authors of this paper express their sincere appreciation
to all CPS–II study participants and to each member of the
study management group. The American Cancer Society
(ACS) funds the creation, maintenance, and updating of the
Cancer Prevention Study II cohort. All of the authors were
employed by the ACS during the course of this analysis.
No ﬁnancial disclosures were reported by the authors of
this paper.References
1. McMenamin TM. A time to work: recent trends in shift work and
ﬂexible schedules. Monthly Labor Statistics, December 2007. www.bls.
gov/opub/mlr/2007/12/art1full.pdf.
2. IARC. Painting, ﬁreﬁghting, and shiftwork. IARC Monographs on the
Evaluation of Carcinogenic Risks to Humans, Volume 98. Geneva:
WHO, 2010.
3. Hansen J. Increased breast cancer risk among women who work
predominantly at night. Epidemiology 2001;12(1):74–7.
4. Lie JA, Roessink J, Kjaerheim K. Breast cancer and night work among
Norwegian nurses. Cancer Causes Control 2006;17(1):39–44.
5. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES.
Night work and breast cancer risk: a systematic review and meta-
analysis. Eur J Cancer 2005;41(13):2023–32.
6. Pronk A, Ji BT, Shu XO, et al. Night-shift work and breast cancer risk
in a cohort of Chinese women. Am J Epidemiol 2010;171(9):953–9.
7. Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. Night work
and risk of breast cancer. Epidemiology 2006;17(1):108–11.
8. Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and
risk of breast cancer in women participating in the Nurses’ Health
Study. J Natl Cancer Inst 2001;93(20):1563–8.
9. Kubo T, Ozasa K, Mikami K, et al. Prospective cohort study of the risk
of prostate cancer among rotating-shift workers: ﬁndings from the
Japan collaborative cohort study. Am J Epidemiol 2006;164(6):549–55.
10. Schernhammer ES, Laden F, Speizer FE, et al. Night-shift work and risk
of colorectal cancer in the Nursesʼ Health Study. J Natl Cancer Inst
2003;95(11):825–8.
11. Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work
and the risk of endometrial cancer. Cancer Res 2007;67(21):10618–22.12. Stevens RG, Hansen J, Costa G, et al. Considerations of circadian
impact for deﬁning “shift work” in cancer studies: IARC Working
Group Report. Occup Environ Med 2011;68(2):154–62.
13. Gachon F, Nagoshi E, Brown SA, Ripperger J, Schibler U. The
mammalian circadian timing system: from gene expression to phys-
iology. Chromosoma 2004;113(3):103–12.
14. Pandi-Perumal SR, Srinivasan V, Spence DW, Cardinali DP. Role of
the melatonin system in the control of sleep: therapeutic implications.
CNS Drugs 2007;21(12):995–1018.
15. Zeitzer JM, Dijk DJ, Kronauer R, Brown E, Czeisler C. Sensitivity of the
human circadian pacemaker to nocturnal light: melatonin phase
resetting and suppression. J Physiol 2000;526(Pt 3):695–702.
16. Cohen M, Lippman M, Chabner B. Role of pineal gland in aetiology
and treatment of breast cancer. Lancet 1978;2(8094):814–6.
17. Baker FC, Driver HS. Circadian rhythms, sleep, and the menstrual
cycle. Sleep Med 2007;8(6):613–22.
18. Voordouw BC, Euser R, Verdonk RE, et al. Melatonin and melatonin–
progestin combinations alter pituitary–ovarian function in women and
can inhibit ovulation. J Clin Endocrinol Metab 1992;74(1):108–17.
19. Martin AM, Weber BL. Genetic and hormonal risk factors in breast
cancer. J Natl Cancer Inst 2000;92(14):1126–35.
20. Blask DE, Brainard GC, Dauchy RT, et al. Melatonin-depleted blood
from premenopausal women exposed to light at night stimulates
growth of human breast cancer xenografts in nude rats. Cancer Res
2005;65(23):11174–84.
21. Shah PN, Mhatre MC, Kothari LS. Effect of melatonin on mammary
carcinogenesis in intact and pinealectomized rats in varying photo-
periods. Cancer Res 1984;44(8):3403–7.
22. Bhatti P, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing
MA. Nightshift work and risk of ovarian cancer. Occup Environ Med
2013;70(4):231–7.
23. Poole EM, Schernhammer ES, Tworoger SS. Rotating night shift work
and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2011;20(5):
934–8.
24. Weiderpass E, Sandin S, Inoue M, et al. Risk factors for epithelial
ovarian cancer in Japan—results from the Japan public health center-
based prospective study cohort. Int J Oncol 2012;40(1):21–30.
25. Garﬁnkel L. Selection, follow-up, and analysis in the American Cancer
Society prospective studies. Natl Cancer Inst Monogr 1985;67:49–52.
26. Calle EE, Rodriguez C, Jacobs EJ, et al. The American Cancer Society
Cancer Prevention Study II Nutrition Cohort: rationale, study design,
and baseline characteristics. Cancer 2002;94(9):2490–501.
27. Kripke DF, Garﬁnkel L, Wingard DL, Klauber MR, Marler MR.
Mortality associated with sleep duration and insomnia. Arch Gen
Psychiatry 2002;59(2):131–6.
28. Kripke DF, Marler MR, Calle EE. Epidemiological health impact. In:
Kushida CA, ed. Sleep deprivation: clinical issues, pharmacology, and
sleep loss effects. Lung biology in health and disease. New York: Marcel
Dekker, 2005:195–208,193.
29. Medicode. Physician ICD-9-CM: 1999–2000 International Classiﬁca-
tion of Diseases clinical modiﬁcation. 6th ed. Ingenix Inc, 1999–2000.
30. WHO. International statistical classiﬁcation of diseases and related
health problems, 10th revision. 2007. apps.who.int/classiﬁcations/
apps/icd/icd10online/.
31. Rodriguez C, Tatham LM, Calle EE, Thun MJ, Jacobs EJ, Heath CW Jr.
Infertility and risk of fatal ovarian cancer in a prospective cohort of
U.S. women. Cancer Causes Control 1998;9(6):645–51.
32. WHO. Obesity and overweight, 2013. www.who.int/mediacentre/
factsheets/fs311/en/.
33. Rodriguez C, Calle EE, Coates RJ, Miracle-McMahill HL, Thun MJ,
Heath CW Jr. Estrogen replacement therapy and fatal ovarian cancer.
Am J Epidemiol 1995;141(9):828–35.
34. Miracle-McMahill HL, Calle EE, Kosinski AS, et al. Tubal ligation and
fatal ovarian cancer in a large prospective cohort study. Am J
Epidemiol 1997;145(4):349–57.www.ajpmonline.org
Carter et al / Am J Prev Med 2014;46(3S1):S34–S41 S4135. Rodriguez C, Henley SJ, Calle EE, Thun MJ. Paracetamol and risk of
ovarian cancer mortality in a prospective study of women in the USA.
Lancet 1998;352(9137):1354–5.
36. Cottreau CM, Ness RB, Kriska AM. Physical activity and reduced risk
of ovarian cancer. Obstet Gynecol 2000;96(4):609–14.
37. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen
replacement therapy and ovarian cancer mortality in a large prospec-
tive study of U.S. women. JAMA 2001;285(11):1460–5.
38. Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ.
Body mass index, height, and the risk of ovarian cancer mortality in a
prospective cohort of postmenopausal women. Cancer Epidemiol
Biomarkers Prev 2002;11(9):822–8.
39. Kurian AW, Balise RR, McGuire V, Whittemore AS. Histologic types
of epithelial ovarian cancer: have they different risk factors? Gynecol
Oncol 2005;96(2):520–30.
40. Herrinton LJ, Stanford JL, Schwartz SM, Weiss NS. Ovarian cancer
incidence among Asian migrants to the United States and their
descendants. J Natl Cancer Inst 1994;86(17):1336–9.
41. Mahoney MM. Shift work, jet lag, and female reproduction. Int J
Endocrinol 2010;2010:813764.
42. Moorman PG, Calingaert B, Palmieri RT, et al. Hormonal risk factors
for ovarian cancer in premenopausal and postmenopausal women. Am
J Epidemiol 2008;167(9):1059–69.March 201443. Stevens RG. Light-at-night, circadian disruption and breast
cancer: assessment of existing evidence. Int J Epidemiol 2009;38(4):
963–70.
44. Dai H, Zhang L, Cao M, et al. The role of polymorphisms in circadian
pathway genes in breast tumorigenesis. Breast Cancer Res Treat
2011;127(2):531–40.
45. Tokunaga H, Takebayashi Y, Utsunomiya H, et al. Clinicopathological
signiﬁcance of circadian rhythm-related gene expression levels in
patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand
2008;87(10):1060–70.
46. Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Meta-
analysis of quantitative sleep parameters from childhood to old age in
healthy individuals: developing normative sleep values across the
human lifespan. Sleep 2004;27(7):1255–73.
47. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int
J Gynecol Pathol 2008;27(2):161–74.Appendix
Supplementary data
Supplementary data associated with this article can be found at,
http://dx.doi.org/10.1016/j.amepre.2013.10.032.
